SOFTMEDX-NEW (00648) has released its interim results for 2026, posting a net profit of HK$4.648 million, a 38.62% increase compared to the same period last year.
Revenue for the period reached HK$34.075 million, reflecting a 4.74% decline year-on-year. Earnings per share stood at HK4.4 cents.
The company attributed the profit growth to a reduction in administrative expenses and the absence of losses from changes in fair value of financial assets measured at fair value through profit or loss.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.